ROVI announces the agreement to market Hirobriz Breezhaler y Ulunar Breezhaler en España


No votes yet
 
Related
ROVI reports operating revenue growth of 23% and EBITDA growth of 68%
Operating revenue increased by 23% to 101.0 million euros in the first quarter of 2020, mainly driven by the strength of the specialty...
7 min
13/05/2020
ROVI signs a co-operation agreement for a clinical trial to study the efficacy and safety of bemiparin in patients hospitalised with pneumonia caused by COVID-19
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has signed a co-operation agreement with Fundación de Investigación HM Hospitales to fund a...
2 min
14/04/2020